Day: August 19, 2021
VICTORIA, British Columbia, Aug. 18, 2021 (GLOBE NEWSWIRE) — Vigil Health Solutions Inc. (“Vigil”) announces the results of operations for the quarter ending June 30, 2021.
Developments in the QuarterRevenue of $1.70 million up 36% from $1.25 million in the three month period ended June 30, 2020.Earnings before income taxes were $281 thousand up 64% from $172 thousand in the three month period ended June 30, 2020.Sales bookings for the quarter were $1.71 million up 41% from $1.21 million in the three month period ended June 30, 2020.Adjusted EBITDA of $320 thousand up 43% from $224 thousand in the three months ended June 30, 2020.“We were pleased to see strong sales bookings and revenue in the quarter. We saw the completion of several projects signed in 2019 and early 2020 that were delayed due to the pandemic. While...
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Written by Customer Service on . Posted in Public Companies.
– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone –
– Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC –
– Study to be presented September 13 at IASLC 2021 World Conference on Lung Cancer –
SHANGHAI, China, and REDWOOD CITY, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung...
Eve & Co. Announces Revenues of $4.0M in the First Half of 2021 and Financial Results for the Six Months Ended June 30, 2021
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
STRATHROY, Ontario, Aug. 18, 2021 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co”, “we”, “us” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF), through its wholly-owned subsidiary, Natural MedCo Ltd. (“NMC”) is pleased to announce that it has made gross revenues of $4.0 million in the first six months of 2021, successfully surpassing its gross revenues of $3.8 million for the entire 2020 financial year.
The Company is also pleased to announce its financial results for the six months ended June 30, 2021 and wishes to highlight the following items;During the first half of 2021, the Company completed additional shipments of EU-GMP certified cannabis to its German customers;
On February 11, 2021, the Company announced that it had successfully completed its first shipment of cannabis products to New Brunswick. Its cannabis...